Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension

(MedPage Today) -- The FDA approved sotatercept (Winrevair) for treating pulmonary arterial hypertension (PAH) in adults, Merck announced on Tuesday. A novel activin signaling inhibitor, sotatercept is indicated to increase exercise capacity...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news